Pre-Close Period Trading Upda
Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Wednesday, 12 January 2011
Dechra® Pharmaceuticals PLC
("Dechra" or the "Group")
Pre-close period Trading Update
The Board of Dechra issues the following trading update ahead of the publication of the Group's Half-Year Results for the six months ended 31 December 2010 which are scheduled to be announced on Tuesday 22 February 2011.
Trading Update
Group revenue for the six months ended 31 December 2010 was approximately 3.9% ahead of the equivalent period last year.
European Pharmaceuticals
European Pharmaceuticals achieved revenue growth of approximately 5.6% compared to the same period last year with all key products showing growth.
US Pharmaceuticals
Revenue from US Pharmaceuticals was ahead of the corresponding period last year by 18.7%. Previously reported supply issues with ophthalmic and otic products have been offset by revenues from DermaPet and increased sales of Vetoryl®.
Product Development
Progress continues to be made on our product development strategy. Three new novel pharmaceutical product opportunities are currently being evaluated, two of which have patent protection.
Services
Revenue from this segment for the six months ended 31 December 2010 was 3.0% up on the equivalent period in the prior year. Continued tight cost control has enabled margins to be substantially held during a period in which trading has been, as expected, highly competitive.
Summary
The trading performance of the Group has continued to be resilient in testing economic conditions. The two acquisitions made during the period are in line with our strategy to develop our international veterinary pharmaceuticals business. They have increased the Group's product portfolio, particularly in the USA where, on the strength of the DermaPet acquisition, we have been able to significantly increase our sales and marketing capability. The Board remains confident that the Group will continue to make positive progress throughout the remainder of the financial year.
|
Enquiries: |
|
|
Ian Page, Chief Executive |
Fiona Tooley, Director |
|
Simon Evans, Group Finance Director |
Keith Gabriel, Senior Account Manager |
|
Dechra Pharmaceuticals PLC |
Citigate Dewe Rogerson |
|
Telephone: + 44 (0) 1782 771100 |
Telephone: +44 (0) 121 362 4035 |
|
Mobile: +44 (0) 777 564 2222 (IP) |
Mobile: +44 (0) 778 570 3523 (FT) |
|
Mobile: +44 (0) 777 564 2220 (SE) |
Mobile: +44 (0) 777 078 8624 (KG) |
corporate.enquiries@dechra.com
Ticker: Sector: Full Listing (Pharmaceuticals): DPH
Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS
Latest directors dealings
- 5 hours ago Luceco
- 5 hours ago Helios Towers
- 6 hours ago Wise Class A
- 6 hours ago EDX Medical Group Plc
- 6 hours ago Naked Wines